Germany's Merck KGaA said on Thursday it is in late-stage talks to acquire U.S.-based SpringWorks Therapeutics for about $3.5 ...

Merck on Thursday said its first-quarter adjusted profit rose 7% as lower costs helped offset a 2% decline in sales, ...

On a per-share basis, the Rahway, New Jersey-based company said it had profit of $2.01. Earnings, adjusted for one-time gains and costs, came to $2.22 per share. The results exceeded Wall Street ...

Germany's Merck is on the verge of a billion-euro takeover of US biopharmaceutical company Springworks Therapeutics, with the ...

I initiate coverage on Merck & Co., Inc. with a Strong Buy rating and a $139 price target, driven by resilient execution and robust product depth. Merck is growing pharma sales and expanding ...

Merck (MRK) released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA is reviewing the application for approval. The data showed that ...

Despite mixed performance, Merck's stock has dropped 37% since mid-2024, but I maintain a buy rating due to long-term support and potential growth drivers. Merck's Q4 results beat expectations ...

Cantor Fitzgerald analyst Carter Gould initiated coverage of Merck (MRK) with a Neutral rating and $85 price target Shares have been “a notable underperformer the past year” as the reset of ...

Merck & Company (MRK – Research Report) received a Hold rating and an $85.00 price target from Cantor Fitzgerald analyst Carter Gould yesterday. The company’s shares closed yesterday at $77.85 ...

A Merck logo is shown on a scientist's lab coat. The Food and Drug Administration, on Sept. 4, 2014, granted accelerated approval to Merck's Keytruda for treating melanoma that has spread or can't be ...

Merck's stock trades at a low valuation as investors worry about Keytruda's looming patent cliff. The company is looking to a new, subcutaneous formulation, which could help sales remain strong ...

Merck & Co.’s subcutaneous (SC) formulation of Keytruda has matched up to the original intravenous (IV) version on two blood concentration measurements, paving way for a potential FDA approval ...